05 Aug Live Beyfortus Educational Webinar
Learn about compelling data for infant RSV immunization to support your immunization efforts for the 2025–2026 RSV season.
Sanofi invites you to attend this session which will focus on Beyfortus® (nirsevimab-alip) 50mg and 100mg and how to effectively implement it in your practice. Topics include:
• Highlight the risk of RSV in infants and the need to protect all infants, including those born before the RSV season.
• Present robust data on Beyfortus, the first long-acting monoclonal antibody for RSV in infants.
• Review AAP, ACIP, and CDC recommendations and offer practical implementation guidance.
There are two live 45-minute events available for your convenience. Login to register.